Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. (Symbol: PALI) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions aimed at preserving the integrity of the intestinal barrier. The company's primary focus is on innovative treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).
Palisade Bio’s strategic product portfolio includes PALI-2108, a promising drug candidate currently under development for treating IBD conditions. The company is also actively researching PALI-1908, a potential therapeutic that may expand its impact in gastrointestinal health.
Recently, Palisade Bio announced significant progress in its pipeline and secured strategic partnerships to further its research and development efforts. Notably, Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the latest offering, underscoring the financial community's confidence in the company's vision and potential.
Palisade Bio's commitment to advancing healthcare solutions is backed by a robust team and dedicated research initiatives. The company frequently updates its stakeholders with the latest developments and forward-looking statements. For more information or inquiries, Jenene Thomas from the JTC Team, LLC can be contacted at 833-475-8247 or via email at PALI@jtcir.com.
Palisade Bio, a biopharmaceutical company focused on gastrointestinal therapies, has received Canadian Patent No. 2,942,358 for LB1148, a serine protease inhibitor that may reduce intestinal damage by neutralizing digestive enzymes. This patent extends protection until 2035. The patent covers the composition of LB1148, which has shown promising results in clinical studies for reducing post-surgical abdominal adhesions and improving gastrointestinal function. Currently, LB1148 is undergoing a Phase 2 study to evaluate its effectiveness in subjects undergoing elective bowel resection, with topline data expected in Q2 2023. The CEO emphasized the importance of strengthening the intellectual property portfolio around LB1148 as part of their development strategy.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
What is Palisade Bio, Inc.'s core business?
What diseases is Palisade Bio targeting with its therapeutics?
What are the key products in Palisade Bio's portfolio?
Who is the exclusive placement agent for Palisade Bio's latest offering?
How can I contact Palisade Bio for more information?
What stage is Palisade Bio in its development?
Does Palisade Bio have any ongoing research projects?
What recent achievements has Palisade Bio announced?
What is the significance of PALI-2108?
Who are the target stakeholders for Palisade Bio's updates?
